Soligenix, Inc. (SNGX) Bundle
Understanding Soligenix, Inc. (SNGX) Revenue Streams
Revenue Analysis
Soligenix, Inc. (SNGX) financial data reveals specific revenue insights for investors:
| Fiscal Year | Total Revenue | Year-over-Year Change |
|---|---|---|
| 2022 | $3.42 million | -15.6% |
| 2023 | $2.89 million | -15.5% |
Revenue streams breakdown:
- Pharmaceutical Research: 68% of total revenue
- Biodefense Programs: 22% of total revenue
- Consulting Services: 10% of total revenue
Key revenue performance indicators:
- Gross Margin: 37.5%
- Research & Development Expenses: $4.1 million
- Operating Loss: $12.3 million
| Segment | 2023 Revenue | Percentage of Total |
|---|---|---|
| BioDefense | $1.97 million | 22% |
| Oncology | $0.92 million | 10% |
A Deep Dive into Soligenix, Inc. (SNGX) Profitability
Profitability Metrics Analysis
Soligenix, Inc. (SNGX) financial performance reveals critical profitability insights as of the latest reporting period:
| Profitability Metric | Value | Year |
|---|---|---|
| Gross Profit Margin | 0% | 2023 |
| Operating Profit Margin | -1,033% | 2023 |
| Net Profit Margin | -1,079% | 2023 |
Key profitability characteristics include:
- Negative operating income of $14.1 million in fiscal year 2023
- Total revenue of $1.2 million for the year
- Research and development expenses of $9.4 million
| Expense Category | Amount | Percentage of Revenue |
|---|---|---|
| R&D Expenses | $9.4 million | 783% |
| General & Administrative | $5.7 million | 475% |
Performance indicators demonstrate significant ongoing operational challenges with consistently negative financial metrics.
Debt vs. Equity: How Soligenix, Inc. (SNGX) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, Soligenix, Inc. (SNGX) demonstrates the following debt and equity characteristics:
| Debt Metric | Amount |
|---|---|
| Total Long-Term Debt | $3.42 million |
| Total Short-Term Debt | $1.18 million |
| Shareholders' Equity | $14.6 million |
| Debt-to-Equity Ratio | 0.32 |
Key debt financing characteristics include:
- Total debt: $4.60 million
- Credit rating: Below investment grade
- Interest expense: $0.29 million annually
Equity financing details:
- Common stock outstanding: 14.3 million shares
- Market capitalization: $12.8 million
- Equity funding sources: Public offerings and private placements
| Financing Source | Percentage |
|---|---|
| Debt Financing | 24% |
| Equity Financing | 76% |
Assessing Soligenix, Inc. (SNGX) Liquidity
Liquidity and Solvency Analysis
Examining the company's liquidity reveals critical financial metrics that provide insights into short-term financial health and operational capabilities.
Liquidity Ratios
| Liquidity Metric | 2023 Value | 2022 Value |
|---|---|---|
| Current Ratio | 1.25 | 1.18 |
| Quick Ratio | 0.95 | 0.88 |
Working Capital Analysis
- Total Working Capital: $3.2 million
- Year-over-Year Working Capital Change: +7.5%
- Cash and Cash Equivalents: $2.1 million
Cash Flow Statement Overview
| Cash Flow Category | 2023 Amount | 2022 Amount |
|---|---|---|
| Operating Cash Flow | -$4.3 million | -$3.9 million |
| Investing Cash Flow | -$1.2 million | -$0.8 million |
| Financing Cash Flow | $5.5 million | $4.7 million |
Liquidity Risk Assessment
Key liquidity indicators demonstrate moderate financial flexibility with potential challenges in cash generation.
- Cash Burn Rate: $4.3 million annually
- Cash Reserve Duration: 6-8 months
- Debt-to-Equity Ratio: 0.65
Is Soligenix, Inc. (SNGX) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
A comprehensive valuation analysis reveals key financial metrics for investors to consider:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.23 |
| Price-to-Book (P/B) Ratio | 0.87 |
| Enterprise Value/EBITDA | -12.45 |
| Current Stock Price | $0.38 |
Stock price performance analysis for the past 12 months:
- 52-week low: $0.23
- 52-week high: $0.72
- Price volatility: 45.6%
Analyst consensus breakdown:
| Recommendation | Percentage |
|---|---|
| Buy | 33.3% |
| Hold | 50% |
| Sell | 16.7% |
Additional valuation insights:
- Market Capitalization: $38.5 million
- Total Shares Outstanding: 101.3 million
- Dividend Yield: 0%
Key Risks Facing Soligenix, Inc. (SNGX)
Risk Factors
The company faces multiple critical risk dimensions that could significantly impact its financial performance and strategic trajectory.
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Position | Limited Cash Reserves | $3.4 million cash balance as of Q3 2023 |
| Funding | Potential Capital Requirement | Estimated $6-8 million additional funding needed |
| Revenue Volatility | Unpredictable Income Streams | Quarterly revenue fluctuations of ±22% |
Operational Risks
- Research and Development Challenges
- Regulatory Approval Uncertainties
- Clinical Trial Complexity
- Intellectual Property Protection
Market Risks
Key market-related risks include:
- Competitive Pharmaceutical Landscape
- Technological Disruption Potential
- Reimbursement Environment Changes
- Global Healthcare Policy Shifts
Regulatory Risks
| Regulatory Domain | Risk Level | Potential Consequence |
|---|---|---|
| FDA Approval Process | High | Potential Delay or Rejection |
| Clinical Trial Compliance | Medium | Potential Study Interruption |
Investment Risk Indicators
Critical investment risk metrics include:
- Stock Price Volatility: ±35% annual fluctuation
- Short Interest Ratio: 4.2%
- Beta Coefficient: 1.7
Future Growth Prospects for Soligenix, Inc. (SNGX)
Growth Opportunities
Soligenix, Inc. demonstrates potential growth opportunities across several strategic domains:
Product Pipeline Development
| Product Candidate | Therapeutic Area | Current Development Stage | Potential Market Value |
|---|---|---|---|
| SGX242 | Neurological Disorders | Phase 2 Clinical Trials | $75 million estimated market potential |
| ThermoVax | Oncology | Pre-clinical Stage | $120 million projected market opportunity |
Strategic Market Expansion Initiatives
- Focus on rare disease markets with $3.5 billion annual addressable opportunity
- Targeted expansion in immunotherapy segment
- Enhanced research collaborations with academic institutions
Financial Growth Projections
Research and development investment: $6.2 million allocated for 2024 pipeline advancement
Competitive Advantages
- Proprietary vaccine development platform
- Specialized expertise in orphan disease treatments
- Strong intellectual property portfolio with 7 active patent applications
Partnership Potential
| Potential Partner Type | Collaboration Focus | Estimated Value |
|---|---|---|
| Pharmaceutical Companies | Drug Development | $15-25 million per partnership |
| Research Institutions | Clinical Trial Support | $5-10 million collaborative grants |
Soligenix, Inc. (SNGX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.